Pharmaceuticals company FDC announced Q4FY24 & FY24 results: Operating Revenue FDC Limited reported an increase in operating revenue, with a 6.3% growth in the fourth quarter (Q4FY24) and an 8.9% growth for the full fiscal year (FY24) compared to the previous corresponding periods. EBITDAs and Profitability The company's EBITDA grew significantly, with an increase of 15.1% for Q4 and 34.9% for the full year. Profit after tax (PAT) for Q4FY24 was reported at Rs 46 crore, showing a growth of 50.9%, and Rs 305 crore for FY24, marking an increase of 57.4% year-over-year. Earnings Per Share (EPS) Earnings Per Share saw a substantial rise for both Q4FY24 and FY24, increasing by 53.7% and 59.3% respectively, indicating a strong performance by the company. Business-wise Sales Breakdown Domestic formulations showed growth, particularly driven by flagship brands such as Electral, Zifi, Enerzal, and Zifi-O. US and Emerging Markets formulating businesses are also trending positively, although US formulations saw a slight decrease in the fourth quarter. API sales exhibited a significant growth of 24.0% for the fourth quarter and an 11.9% increase for the fiscal year. Geographical Revenue Contributions Revenue from international operations, specifically in the US and Rest of the World (ROW) markets, has been notable, with consolidated revenue showing a 12% increase. The export formulations accounted for 15% of the total consolidated revenue. Result PDF
Pharmaceuticals company FDC announced Q2FY24 & H1FY24 results: Q2FY24: Operating Revenue: Rs 486 crore, a solid 9.3% YoY growth. EBITDA: Rs 76 crore, up by 13.5% YoY. EBITDA Margin: 15.2%. PBT: Rs 93 crore, a notable 34.3% YoY increase. PAT: Rs 70 crore, showing a strong 34.7% YoY growth. EPS: Rs 4.22, with a significant 36.2% YoY increase. H1FY24: Operating Revenue: Rs 1,023 crore, an 8.8% YoY growth. EBITDA: Rs 198 crore, a substantial 36.5% YoY increase. EBITDA Margin: 19.4%. PBT: Rs 233 crore, with a remarkable 49.6% YoY growth. PAT: Rs 180 crore, showing a notable 46.7% YoY increase. EPS: Rs 10.84, with a strong 47.5% YoY growth. Commenting on the results, the company said, "During Q2FY24 and H1FY24, we are pleased to announce that we have achieved growth across all our business segments in Domestic as well as International business. The major driver growth in the Domestic Formulation business is laid by the flagship brands, Electral, Zifi, Enerzal and Zifi-O. Growth in the International Formulation business is primarily laid by the US market growing by 31.7% during H1FY24. Further, the margins and profitability have shown significant improvements during the quarter as well as H1FY24 attributable primarily to improved sale realisation, lower cost of goods sold, and lower operating expenses." Result PDF
Pharmaceuticals company FDC announced Q1FY24 results: Operating revenue of Rs 536 crore in Q1FY24 compared to Rs 495 crore in Q1FY23, up 8.4% YoY EBITDA of Rs 122 crore in Q1FY24 compared to Rs 78 crore in Q1FY23, up 56.4% YoY EBITDA% of 22.7% in Q1FY24 compared to 15.8% in Q1FY23 PBT of Rs 141 crore in Q1FY24 compared to Rs 87 crore in Q1FY23, up 61.7% YoY PAT of Rs 110 crore in Q1FY24 compared to Rs 71 crore in Q1FY23, up 55.4% YoY EPS of Rs 6.62 in Q1FY24 compared to Rs 4.23 in Q1FY23, up 56.6% YoY Commenting on the results, management said, "We are pleased to announce that we have achieved growth across all our business segments in the current quarter. Our domestic business segment reported growth of 6% during the quarter, albeit under some price pressure. Notably, our Export Formulation and API business segments exhibited robust YoY growth of 19%. Furthermore, we are delighted to report that our margins and profits have shown improvement which is attributed due to improved sales realization and an increase in other income. We remain focused on sustaining and building upon these advancements in the upcoming periods." Result PDF